Compare Heron Therapeutics Inc (HRTX) vs OneSpan Inc (OSPN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs OneSpan Inc — how do they compare? Heron Therapeutics Inc trades at $0.41 (market cap $68.01M), while OneSpan Inc trades at $18.22 (market cap $662.97M). The key difference: OneSpan Inc is far larger — about 9.7× Heron Therapeutics Inc's market cap, and OneSpan Inc pays a 2.89% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Heron Therapeutics Inc for 35 Days and OneSpan Inc for 18 Days on average.
| HRTX | OSPN | |
|---|---|---|
Market Cap | $68.01M | $662.97M |
Volume | 1,891,941 | 616,882 |
Sector | Health | Technology |
52-Week High | $1.49 | $18.42 |
52-Week Low | $0.27 | $10.15 |
Typical Hold Time | 35 Days | 18 Days |
Enterprise Value | $174.75M | $632.05M |
Dividend Yield | — | 2.89% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Heron Therapeutics (HRTX) trades at $0.4061, up 4.13% today, with a bullish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7M but missed EPS estimates with a $0.03 loss. Despite negative profitability metrics (-22.52% net margin), analyst consensus remains strongly positive with 89% buy ratings. Recent news highlights ongoing comparisons with peers and earnings call discussions.
HRTX faces significant fundamental challenges with consistent losses and negative ROE, though revenue stability provides some foundation. The strong analyst support suggests potential upside if operational improvements materialize, but high execution risk and cash flow concerns warrant caution for investors seeking near-term profitability.
OSPN trades at $18.22, up 2.94% today, with a bullish technical signal from moving averages and recent earnings beats. The company shows strong profitability with a 27.76% net income margin and a reasonable P/E of 10.16. Analyst consensus is strongly positive with 10 buy ratings. Recent news highlights investor attention and a new product launch, DigipassONE, supporting growth prospects.
The outlook for OSPN is favorable given consistent earnings outperformance and solid fundamentals, though negative net cash flow and competitive pressures pose risks. Upside potential hinges on execution of its subscription revenue growth strategy and market adoption of new authentication solutions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About OneSpan Inc
OneSpan Inc. is a global leader in providing digital agreement security solutions. The company's platform helps organizations, primarily in the financial services sector, to secure their digital agreements and transactions, including e-signatures, multi-factor authentication, and transaction monitoring. OneSpan's technology is focused on protecting customers from fraud and meeting regulatory compliance requirements in a digital-first environment.
Read more on OSPN →
